Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 13,585 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatoses Clear all
Completed Not applicable Interventional

Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer

NCT03233555
View directory record Official record
Conditions
Stage I Breast Cancer, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Prostate Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage II Colorectal Cancer AJCC v7, Stage II Prostate Cancer, Stage IIA Breast Cancer, Stage IIA Colorectal Cancer AJCC v7, Stage IIA Prostate Cancer, Stage IIB Breast Cancer, Stage IIB Colorectal Cancer AJCC v7, Stage IIB Prostate Cancer, Stage IIC Colorectal Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7
Interventions
Informational Intervention, Internet-Based Intervention, Quality-of-Life Assessment, Questionnaire Administration, Telephone-Based Intervention
Other · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
30 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
2
States / cities
New Brunswick, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Not applicable Interventional Results available

To Enhance Breast Cancer Survivorship of Asian Americans

NCT02803593
View directory record Official record
Conditions
Breast Cancer
Interventions
Technology-based information and coaching/support program, American Cancer Society information on breast cancer
Behavioral
Lead sponsor
Emory University
Other
Eligibility
21 Years and older · Female only
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Atlanta, Georgia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

NCT02039947
View directory record Official record
Conditions
Melanoma and Brain Metastases
Interventions
Dabrafenib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Phase 2 Interventional

Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer

NCT00002826
View directory record Official record
Conditions
Breast Cancer
Interventions
paclitaxel, valspodar
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
9
States / cities
Palo Alto, California • Stanford, California • Flemington, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 23, 2026, 6:39 AM EDT
Terminated No phase listed Observational

Photoacoustic Lymph Node Imaging

NCT03931655
View directory record Official record
Conditions
Breast Cancer
Interventions
Spectroscopic photoacoustic imaging
Diagnostic Test
Lead sponsor
Geoff Luke
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 23, 2026, 6:39 AM EDT
Withdrawn Phase 1 Interventional

Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer

NCT00706615
View directory record Official record
Conditions
Breast Cancer
Interventions
Ad-sig-hMUC-1/ecdCD40L vaccine
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 23, 2026, 6:39 AM EDT
Recruiting Phase 2 Interventional

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

NCT07219615
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg, Placebo - 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 23, 2026, 6:39 AM EDT
Terminated Phase 1 Interventional

Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer

NCT02474173
View directory record Official record
Conditions
Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Onalespib, Paclitaxel, Pharmacological Study
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Lexington, Kentucky • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 23, 2026, 6:39 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Open-Label Study of TPI 287 for Patients With Metastatic Melanoma

NCT01340729
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
TPI 287
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 23, 2026, 6:39 AM EDT
Terminated Phase 3 Interventional Results available

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

NCT04410445
View directory record Official record
Conditions
Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin)
Interventions
Bempegaldesleukin, Nivolumab
Biological
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
765 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
62
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 23, 2026, 6:39 AM EDT
Terminated Phase 3 Interventional Results available

A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea

NCT03564145
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
S5G4T-1
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Phase 2 Interventional

A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma

NCT01009775
View directory record Official record
Conditions
Melanoma
Interventions
YM155, Docetaxel
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
12
States / cities
Mobile, Alabama • Tuscon, Arizona • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2015 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa

NCT04856930
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Imsidolimab, Placebo
Biological
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
17
States / cities
Birmingham, Alabama • Fountain Valley, California • Northridge, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 23, 2026, 6:39 AM EDT
Recruiting Phase 2 Interventional

FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)

NCT07111065
View directory record Official record
Conditions
Dermatomyositis (DM), Juvenile Dermatomyositis (JDM)
Interventions
FISH OIL 500MG OMEGA-3 SOFT GEL MINIS, Placebo
Dietary Supplement
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Not applicable Interventional

The Use of Smart Scales for Weight Gain Prevention in African American Breast Cancer Survivors

NCT02030353
View directory record Official record
Conditions
Body Weight Changes, Breast Neoplasms
Interventions
Self-regulation plus activity monitoring, Self-regulation
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Risk Information and Skin-cancer Education for Undergraduate Prevention

NCT03979872
View directory record Official record
Conditions
Melanoma, Young Adult
Interventions
MC1R Genetic Testing, Skin Cancer Education, UV Photo
Diagnostic Test · Other · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 23, 2026, 6:39 AM EDT
Terminated Phase 1 Interventional

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

NCT04261439
View directory record Official record
Conditions
In Escalation: All Patients With Solid Tumors and Lymphoma, In Expansion: Melanoma, Non-small Cell Lung Cancer
Interventions
NIZ985, Spartalizumab, Tislelizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Duarte, California • La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Phase 3 Interventional Results available

PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01212757
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo + 20 mg Apremilast, Placebo + 30 mg Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
23
States / cities
Tuscaloosa, Alabama • Denver, Colorado • Trumbull, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 23, 2026, 6:39 AM EDT
Terminated Phase 2 Interventional Results available

Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy

NCT01855607
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Neuropathy
Interventions
topical menthol, placebo lotion
Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 23, 2026, 6:39 AM EDT
Not listed No phase listed Observational

Dermatomyositis and Polymyositis Registry

NCT01637064
View directory record Official record
Conditions
Dermatomyositis, Polymyositis
Interventions
Acthar
Drug
Lead sponsor
Phoenix Neurological Associates, LTD
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
5
States / cities
Phoenix, Arizona • San Diego, California • Columbia, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

NCT02586987
View directory record Official record
Conditions
Lung Cancer, Melanoma, Head and Neck Carcinoma, Gastroesophageal Cancer, Breast Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Biliary Tract Cancer
Interventions
Selumetinib, MEDI4736, Tremelimumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 23, 2026, 6:39 AM EDT
Not listed Phase 2 Interventional

Systemic Uptake of Diclofenac Sodium in Combination With Miconazole as Antifungal Nail Gel When Applied Daily With Monitoring of Hepatic and Renal Enzymes, and Serum Levels of Diclofenac 12 Hours After Application, and at 3 and 6 Months Study

NCT04341402
View directory record Official record
Conditions
Tinea Unguium, Onychomycosis
Interventions
Antifungal Nail Gel Study
Drug
Lead sponsor
William N Handelman
Other
Eligibility
21 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Not applicable Interventional Results available

Nueva Vida Intervention for Latina Breast Cancer Survivors and Caregivers

NCT02222337
View directory record Official record
Conditions
Quality of Life, Breast Cancer
Interventions
Nueva Vida Intervention
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
Up to 85 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
San Jose, California • Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Oct 23, 2026, 6:39 AM EDT
Terminated Phase 2 Interventional Results available

Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells

NCT01495572
View directory record Official record
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
Fludarabine, Cyclophosphamide, Aldesleukin, MART-1 Reactive CD8+ PBL
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Oct 23, 2026, 6:39 AM EDT